NL-OMON27495
Recruiting
Not Applicable
Prostate Cancer Molecular Medicine (PCMM).
Erasmus MC, NKI-AvL, UMCG, UMC0 sites400 target enrollmentTBD
ConditionsProstate cancer / prostaatkanker
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate cancer / prostaatkanker
- Sponsor
- Erasmus MC, NKI-AvL, UMCG, UMC
- Enrollment
- 400
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Planned to undergo prostate biopsies according to standard practice;
Exclusion Criteria
- •Group 1 and group 2:
- •1\. Known allergy to contrast agents or sulphur hexafluoride micro bubbles;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prostate Cancer Molecular MedicineProstate cancerprostate carcinoma1003859710036958NL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
Completed
Not Applicable
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)NL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
Terminated
Not Applicable
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate CancerProstate CancerNCT00122265AHS Cancer Control Alberta83
Recruiting
Not Applicable
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate CancerCastration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)NCT06600802Centre Jean Perrin120
Recruiting
Not Applicable
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese PopulationProstate CancerNCT03893929Chinese University of Hong Kong5,000